Adherence to Anti–Tumor Necrosis Factor Therapy Administered Subcutaneously and Associated Factors in Patients With Rheumatoid Arthritis
- 1 December 2015
- journal article
- research article
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 21 (8) , 419-425
Abstract
Background Adherence to biologic therapy is relatively poorly studied in rheumatoid arthritis (RA) because many of the studies have investigated the drug persistence, which represents only a surrogate of adherence. Objectives The aims of this study were to determine the extent of adherence in RA patients with subcutaneously administered anti–tumor necrosis factor methotrexate agents and to identify the risk factors for nonadherence. Methods A cohort of RA patients who started a subcutaneous anti–tumor necrosis factor treatment were enrolled. After 12 months of treatment, all patients completed the 4-item Morisky Medication Adherence Scale questionnaire. Associations between beliefs and nonadherence and the influence of demographic, clinical, and radiographic features were assessed using logistic regression model. Results A total of 209 (80.4%) of the 260 patients were included in the analyses. Forty-three of 209 patients were considered nonadherent to their medication (20.6%) according to the 4-item Morisky Medication Adherence Scale. More than half (53.1%) of patients showed at least 1 form of nonadherent behavior. The logistic model showed that low disease activity (P = 0.003), higher patient-physician discordance ratings (P = 0.012), older age (P = 0.041), and a high number of comorbid conditions (P = 0.011) were significantly associated with increased likelihood of nonadherence. Conclusions The overall nonadherence with subcutaneous biologic therapy is relatively high among RA patients and should be taken into account when a patient’s response to treatment is unsatisfactory.Keywords
This publication has 37 references indexed in Scilit:
- Electronic Monitoring of Oral Therapies in Ethnically Diverse and Economically Disadvantaged Patients With Rheumatoid Arthritis: Consequences of Low AdherenceArthritis & Rheumatism, 2013
- Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologicsCurrent Medical Research and Opinion, 2010
- Inadequate Therapy Behavior Is Associated to Disease Flares in Patients With Rheumatoid Arthritis Who Have Achieved Remission With Disease-Modifying Antirheumatic DrugsThe American Journal of the Medical Sciences, 2010
- Patient‐physician discordance in assessments of global disease severity in rheumatoid arthritisArthritis Care & Research, 2010
- Test-Retest Reliability of Patient Global Assessment and Physician Global Assessment in Rheumatoid ArthritisThe Journal of Rheumatology, 2009
- Medication Adherence of Patients with Selected Rheumatic Conditions: A Systematic Review of the LiteratureSeminars in Arthritis and Rheumatism, 2009
- Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disabilityArthritis Research & Therapy, 2009
- Adherence to MedicationNew England Journal of Medicine, 2005
- A self‐administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic researchArthritis & Rheumatism, 1995
- Concurrent and Predictive Validity of a Self-reported Measure of Medication AdherenceMedical Care, 1986